Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drug dapagliflozin put to the test against standard care

NCT ID NCT02616666

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug dapagliflozin (Forxiga) works better than standard treatments for people with type 2 diabetes whose blood sugar is not well controlled on metformin alone. Over 600 adults took either dapagliflozin plus metformin or usual care (like sulfonylureas). Researchers tracked blood sugar control, weight loss, and safety for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (brand name Forxiga), a tablet taken by mouth
What this could lead to
If successful, this could show that dapagliflozin helps more people achieve better blood sugar control and weight loss without increasing hypoglycemia risk compared to usual treatments.
What could go wrong
This is a completed Phase 4 trial, so results are already known. However, it was relatively small (632 people) and may not apply to all diabetes patients. Dapagliflozin can cause side effects like urinary infections or dehydration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

632 people

The number who actually took part.

Started

Aug 2016

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria at the time of screening: 1. Provision of informed consent prior to any study specific procedures 2. Females and males aged ≥18 years up to ≤ 75 years 3. Diagnosed with Type 2 Diabetes Mellitus. 4. Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c \> 6.5%. 5. Ability to read and write as judged by the investigator. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) 2. Previous enrolment or randomization in the present study 3. Age \> 75 years 4. Pregnancy/active breast feeding at the time of inclusion 5. Known moderate to severe renal impairment (eGFR\<60ml/min). 6. Participation in an interventional clinical trial ≤ 3 months before enrolment. 7. Unsuitable to participate on mental health grounds, as judged by the investigator. 8. Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin. 9. Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Forfar, Angus, United Kingdom

  • Research Site

    Yate, Avon, United Kingdom

  • Research Site

    Bracknell, Berkshire, United Kingdom

  • Research Site

    Reading, Berkshire, United Kingdom

  • Research Site

    Wokingham, Berkshire, United Kingdom

  • Research Site

    Maesteg, Bridgend, United Kingdom

  • Research Site

    Chew Stoke, Bristol, United Kingdom

  • Research Site

    Yate, Bristol, United Kingdom

  • Research Site

    Iver, Bucks, United Kingdom

  • Research Site

    Blackwood, Caerphilly, United Kingdom

  • Research Site

    Hengoed, Caerphilly, United Kingdom

  • Research Site

    Greenisland, Carrickfergus, United Kingdom

  • Research Site

    Whitehead, Carrickfergus, United Kingdom

  • Research Site

    Macclesfield, Cheshire, United Kingdom

  • Research Site

    Crook, County Durham, United Kingdom

  • Research Site

    Denbigh, Denbighshire, United Kingdom

  • Research Site

    Exeter, Devon, United Kingdom

  • Research Site

    Hull, East Yorkshire, United Kingdom

  • Research Site

    Romford, Essex, United Kingdom

  • Research Site

    Pinhoe, Exeter, United Kingdom

  • Research Site

    Cheltenham, Gloucestershire, United Kingdom

  • Research Site

    Trafford, Greater Manchester, United Kingdom

  • Research Site

    Worsley, Greater Manchester, United Kingdom

  • Research Site

    Alton, Hampshire, United Kingdom

  • Research Site

    Farnborough, Hampshire, United Kingdom

  • Research Site

    Gosport, Hampshire, United Kingdom

  • Research Site

    Havant, Hampshire, United Kingdom

  • Research Site

    Romsey, Hampshire, United Kingdom

  • Research Site

    Southampton, Hampshire, United Kingdom

  • Research Site

    Waterlooville, Hampshire, United Kingdom

  • Research Site

    Winchester, Hampshire, United Kingdom

  • Research Site

    Southampton, Hants, United Kingdom

  • Research Site

    Leominster, Herefordshire, United Kingdom

  • Research Site

    Fortrose, Highland, United Kingdom

  • Research Site

    Beckenham, Kent, United Kingdom

  • Research Site

    Canterbury, Kent, United Kingdom

  • Research Site

    Faversham, Kent, United Kingdom

  • Research Site

    Gravesend, Kent, United Kingdom

  • Research Site

    Rainham, Kent, United Kingdom

  • Research Site

    Barnoldswick, Lancashire, United Kingdom

  • Research Site

    Blackburn, Lancashire, United Kingdom

  • Research Site

    Darwen, Lancashire, United Kingdom

  • Research Site

    Lancaster, Lancashire, United Kingdom

  • Research Site

    Nelson, Lancashire, United Kingdom

  • Research Site

    Thornton-Cleveleys, Lancashire, United Kingdom

  • Research Site

    Thornton-Cleveleys, Lancs, United Kingdom

  • Research Site

    Loughborough, Leicestershire, United Kingdom

  • Research Site

    Balham, London, United Kingdom

  • Research Site

    Brockley, London, United Kingdom

  • Research Site

    London, London, United Kingdom

  • Research Site

    Rotherhithe, London, United Kingdom

  • Research Site

    Streatham, London, United Kingdom

  • Research Site

    Trafford, Manchester, United Kingdom

  • Research Site

    Liverpool, Merseyside, United Kingdom

  • Research Site

    Metropolitan Borough of Wirral, Merseyside, United Kingdom

  • Research Site

    Wembley, Middlesex, United Kingdom

  • Research Site

    Glyncorrwg, Neath Port Talbot, United Kingdom

  • Research Site

    Newport, Newport, United Kingdom

  • Research Site

    Swaffham, Norfolk, United Kingdom

  • Research Site

    Clevedon, North Somerset, United Kingdom

  • Research Site

    Pickering, North Yorkshire, United Kingdom

  • Research Site

    Ripon, North Yorkshire, United Kingdom

  • Research Site

    Nottingham, Nottinghamshire, United Kingdom

  • Research Site

    Nottingham, Notts, United Kingdom

  • Research Site

    Bicester, Oxfordshire, United Kingdom

  • Research Site

    Carterton, Oxfordshire, United Kingdom

  • Research Site

    Oxford, Oxfordshire, United Kingdom

  • Research Site

    Wantage, Oxfordshire, United Kingdom

  • Research Site

    Witney, Oxfordshire, United Kingdom

  • Research Site

    Oxford, Oxford, United Kingdom

  • Research Site

    Oxford, Oxon, United Kingdom

  • Research Site

    Milford Haven, Pembrokeshire, United Kingdom

  • Research Site

    Tonypandy, Rhondda Cynon Taff, United Kingdom

  • Research Site

    Pontypridd, Rhondda Cynon Taf, United Kingdom

  • Research Site

    Telford, Shropshire, United Kingdom

  • Research Site

    Axbridge, Somerset, United Kingdom

  • Research Site

    Ayr, South Ayrshire, United Kingdom

  • Research Site

    Conisbrough, South Yorkshire, United Kingdom

  • Research Site

    Worsborough, South Yorkshire, United Kingdom

  • Research Site

    Bury St Edmunds, Suffolk, United Kingdom

  • Research Site

    Camberley, Surrey, United Kingdom

  • Research Site

    Guildford, Surrey, United Kingdom

  • Research Site

    London, Surrey, United Kingdom

  • Research Site

    Killay, Swansea, United Kingdom

  • Research Site

    Barry, Vale of Glamorgan, United Kingdom

  • Research Site

    Nuneaton, Warks, United Kingdom

  • Research Site

    Alcester, Warwickshire, United Kingdom

  • Research Site

    Atherstone, Warwickshire, United Kingdom

  • Research Site

    Bidford-on-Avon, Warwickshire, United Kingdom

  • Research Site

    Nuneaton, Warwickshire, United Kingdom

  • Research Site

    Stratford-upon-Avon, Warwickshire, United Kingdom

  • Research Site

    Warwick, Warwickshire, United Kingdom

  • Research Site

    Walsall, West Midlands, United Kingdom

  • Research Site

    Wolverhampton, West Midlands, United Kingdom

  • Research Site

    Crawley, West Sussex, United Kingdom

  • Research Site

    Swindon, Wiltshire, United Kingdom

  • Research Site

    Droitwich, Worcestershire, United Kingdom

  • Research Site

    Kidderminster, Worcestershire, United Kingdom

  • Research Site

    Malvern, Worcestershire, United Kingdom

  • Research Site

    Alton, United Kingdom

  • Research Site

    Altrincham, United Kingdom

  • Research Site

    Blackburn, United Kingdom

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Cirencester, United Kingdom

  • Research Site

    Cockermouth, United Kingdom

  • Research Site

    Colchester, United Kingdom

  • Research Site

    Colindale, United Kingdom

  • Research Site

    Dudley, United Kingdom

  • Research Site

    Edmonton, United Kingdom

  • Research Site

    Fareham, United Kingdom

  • Research Site

    Fleet, United Kingdom

  • Research Site

    Gravesend, United Kingdom

  • Research Site

    Hull, United Kingdom

  • Research Site

    Kings Norton, United Kingdom

  • Research Site

    Langport, United Kingdom

  • Research Site

    Liphook, United Kingdom

  • Research Site

    Liverpool, United Kingdom

  • Research Site

    London, N8, United Kingdom

  • Research Site

    Maryport, United Kingdom

  • Research Site

    Morriston, United Kingdom

  • Research Site

    Oxford, OX2, United Kingdom

  • Research Site

    Petersfield, United Kingdom

  • Research Site

    Rowlands Castle, United Kingdom

  • Research Site

    Royal Leamington Spa, United Kingdom

  • Research Site

    Stansted, United Kingdom

  • Research Site

    Stratford-upon-Avon, United Kingdom

  • Research Site

    Torquay, United Kingdom

  • Research Site

    Wallsend, United Kingdom

  • Research Site

    Waterlooville, United Kingdom

  • Research Site

    Wembley, United Kingdom

  • Research Site, Alum Rock

    Birmingham, Birmingham, United Kingdom

  • Research Site, Market Square

    Kineton, Kineton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.